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Progress Report 
Scientific Goals. Proteolysis of lung elastin and other connective tissue 
proteins releasedT-OF-leukocytes is generally thought to cause the destruction of the 
lung which is observed in pulmonary emphysema. The two major serine proteases of 
leukocytes, human leukocyte elastase and cathepsin G, will hydrolyze lung elastin. In 
addition to emphysema, elastase is involved in amyloidosis and chronic inflanmation, 
while pancreatic elastase is involved in pancreatitis. Cathepsin C and other 
chynotrypsin-like enzymes from mast cells are speculated to play a role in inflammation 
and arthritis. 
The goal of this research is to develop an elastase inhibitor which would be useful 
for the treatment of human emphysema. A variety of structures will be investigated 
including heterocyclic structures which may he transition state analogs, heterocyclic 
mechanism based inhibitors, peptide analogs, and selective acylatinq agents. All the 
inhibitors will be tested with cathepsin G and other chymotrypsin-like enzymes. Any 
promising inhibitors will be provided to other investigators for studies in animal 
models of emphysema. This research should lead to a better understanding of active site 
structures of the enzymes involved in connective tissue turnover and should lead to new 
theapeutic methods for the treatment of pulmonary emphysema. 
Progress. During the first year of this grant, we have discovered a new mechanism 
based elastase inhibitor which I believe has considerable potential for use in treatment 
of human emphysema. At present I have discerned no negative features to this inhibitor 
and one of our next steps will be to encourage other investigators to test this 
inhibitor in animals. The inhibitor is 3-chloroisocoumarin. 
Mechanism based irreversible inhibitors, which have been reported for porcine 
PAGE 6 	(Use Continuation Page as necessary) PHS 2590 (Rev. 5/82) 
Powers, James C. HL29307-02 
pancreatic (PP) elastase and bovine pancreatic chymotrypsin A , include 
6-halomethylcoumarins, nitroso lactams, haloenol lactones, isatoic anhydride and 
3H-1,3-oxazine-2,6-diones. Human leukocyte (HL) elastase and cathepsin G are inhibited 
reversibly by heterocyclic structures such as 2-substituted-4H-3,1=buzoxazin-4-ones and 
N-arylbenzisothiazolinone 1,1-dioxides. 	This suggested that heteroZtclics containing 
masked reactive functionalities might act as mechanism based irreversible inhibitors for 
HL elastase and cathepsin G, enzymes for which no such inhihitors has been demonstrated. 
Therefore we prepared 3-chloroisocoumarin (1) 	and 3,3-dichlorophthalide (2) and have 
found then to be potent irreversible inhibirs  of several serine proteases. 
2. 
Incubation of 1 and 2 with HL elastase, PP elastase, and chymotrypsin A 	resulted 
in a rapid time depTndent inhibition of enzyme activity. Cathepsin G was only inhibited 
by 2 , and 1 did not inhibit trypsin or the cysteine protease papain. In all cases the 
inhibition Tate was dependent upon inhibitor concentration. Rates of inhibition of HL 
and PP elastase were decreased dramatically when the reversible inhibitors 
2-pentafluoropropy1•4H-3,1-benzoxazin-4-one and CF 1CO-Lys-Ala-NHCH4CH, 
were added respectively to the incubation solutiong , indicating that ttie inhibitors are 
active site directed. 
HL and PP elastase inhibited by 1 were quite stahle to reactivation upon standing, 
while cathepsin G, chymotrypsin and aTI the enzymes inhibited with 2 regained activity 
upon standing. The presence of labile acyl moieties in the inhibited protease was also 
indicated by the rapid reactivation ( < 4 min) of HL and PP elastase inactivated by 1 
when buffered hydrazine (1-3 mil was added. 
Hydrolysis of 1 to 2-carboxyphenylacetic acid (honophthalic acid) in the presence 
and absence of enzyTe could be monitored by an absorbance decrease at 325 nn. The rate 
increased when enzyme was added indicating that the enzyme was turning over the 
inhibitor. This is a characteristic of mechanism based inhibitors. Other studies 
suggested >15 turnovers/inactivation for HL elastase and >4 for PP elastase. The 
reaction of 1 with chymotrypsin A is almost stoichiometric since 1.0 equivalent of 1 
resulted in 70 % inhibition. 
Reaction of 1 with chymotrypsin A in aqueous solution utilizing a pH stat resulted 
in the rapid rele-a-se of 0.92 equivalents of protons after 6 min at which time the 
residual enzymatic activity was 9.8 %. Similar experiment with 2 and chymotrypsin A 
resulted in the release of 2.7 equivalents of protons after 15 Min at which time the 
enzymatic activity was 8 %. Further incubation resulted in the release of 3.1 total 
protons with 1 (theoretical 3) after 115 nin. At pH 8.5 under identical conditions, 1 
reacted with Z-hymotrypsin A 	to release 0.95 protons within 3 min and slowly released - 
the additional protons over the course of 1 hr. 
The above results are consistent with the following scheme where serine proteases 
react with 3-chloroisocoumarin 1 with the formation of the acyl enzyme 3 by reaction at 
the active site serine residue. Formation of the diacylated product 4 Then occurs by 
reaction at histidine-57, the only likely nucleophile in the active site of most serine 
proteases. The alternate structure in which a protonated histidine interacts with the 
inhibitor to form a stabilized acyl enzyme can he ruled out by the pH stat results. 
Only one proton would be released at pH 7.5 if the pK of the histidine was increased due 
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to a favorable electrostatic interaction with the inhibitor carboxyl group. However at 
higher pHs, one would expect 2 protons to be released and this was not observed. 
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The evidence indicates that 1 and 2 are mechanism based irreversible inhibitors of 
serine proteases. These are the "first dTmonstrated examples of enzyme activated 
inhibitors of HL elastase and cathepsin G. These enzymes have been noted to he major 
contributors to elastin destruction observed in emphysema. 	These inhibitors and 
similar structures nay have considerable pharmacologic potential as inhibitors in vivo . 
Specific Objectives for Next Year. Studies leading to a clearer understanding of 
the inhibition processes iriaTeFiritET reaction of HL elastase with 3-chlorocounarin 
are now in progress. We are testing the solublity and stablity of 3-chlorocoumarin in 
preparation for getting it tested in animals. We will also test the reactivity of 
3-chloroisocoumarin toward nucleophiles such as glutathione and its life-time in plasma. 
At the same time, we are trying to extend this lead by synthesizing other structures 
which are capable of reacting with HL elastase releasing reactive functional groups. In 
particular, we are examining structures which contain masked chloromethyl ketone 
functional groups. When this group is unmasked, it could potentially alkylate the 
histidine of elastase. 
We are also cooperating with Dr. Edgar Meyer at Texas A A M on an x-ray study of 
structure of PP elastase inhibited by 3-chloroisocoumarin. He plans to collect a data 
set on the enzyme inhibitor complex during the summer while he is in Huher's lab in 
Germany. This fall, I plan to make a trip to Texas to do some modeling in Dr. Meyer's 
lab. No x-ray structure on HL elastase is yet available. However, modeling with the 
structure of the closely related enzyme PP elastase often yields valuable insights for 
the design of HL elastase inhibitors. 
Since we have spent all of our recent effort on the mechanism based inhibitors, we 
have not yet started some of the other problems which we orginally proposed. However, I 
have a new postdoc from Japan (Dr. Hori) starting in August. He will probably work 
either on the acylating agents for elastase or the peptide transition state inhibitors 
which we described in the orginal proposal. 
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